150 related articles for article (PubMed ID: 7772519)
1. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS).
Rose EH; Abels RI; Nelson RA; McCullough DM; Lessin L
Br J Haematol; 1995 Apr; 89(4):831-7. PubMed ID: 7772519
[TBL] [Abstract][Full Text] [Related]
2. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of recombinant human erythropoietin therapy in myelodysplastic syndromes.
Adamson JW; Schuster M; Allen S; Haley NR
Acta Haematol; 1992; 87 Suppl 1():20-4. PubMed ID: 1574963
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
5. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
Henry DH; Beall GN; Benson CA; Carey J; Cone LA; Eron LJ; Fiala M; Fischl MA; Gabin SJ; Gottlieb MS
Ann Intern Med; 1992 Nov; 117(9):739-48. PubMed ID: 1416576
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
[TBL] [Abstract][Full Text] [Related]
8. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia.
van Kamp H; Prinsze-Postema TC; Kluin PM; den Ottolander GJ; Beverstock GC; Willemze R; Fibbe WE
Br J Haematol; 1991 Aug; 78(4):488-93. PubMed ID: 1911340
[TBL] [Abstract][Full Text] [Related]
9. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
11. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
[TBL] [Abstract][Full Text] [Related]
12. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin.
Bowen D; Culligan D; Jacobs A
Br J Haematol; 1991 Mar; 77(3):419-23. PubMed ID: 2012769
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
Stein RS; Abels RI; Krantz SB
Blood; 1991 Oct; 78(7):1658-63. PubMed ID: 1912554
[TBL] [Abstract][Full Text] [Related]
14. High-dose recombinant human erythropoietin administered intravenously for the treatment of anaemia in myelodysplastic syndromes.
Casadevall N; Belanger C; Goy A; Varet B; Lang J; Poisson D
Acta Haematol; 1992; 87 Suppl 1():25-7. PubMed ID: 1574964
[TBL] [Abstract][Full Text] [Related]
15. The effect of subcutaneous r-HuEPO in cancer patients receiving chemotherapy with anemia: a preliminary report.
Chiou TJ; Chim YS; Wei CH; Hsieh RK; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Nov; 60(5):229-35. PubMed ID: 9509677
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group.
Kulzer P; Schaefer RM; Krahn R; Schaefer L; Heidland A
Int J Artif Organs; 1994 Apr; 17(4):195-202. PubMed ID: 8070941
[TBL] [Abstract][Full Text] [Related]
17. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.
Sweeney PJ; Nicolae D; Ignacio L; Chen L; Roach M; Wara W; Marcus KC; Vijayakumar S
Br J Cancer; 1998 Jun; 77(11):1996-2002. PubMed ID: 9667681
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study.
Shannon KM; Mentzer WC; Abels RI; Freeman P; Newton N; Thompson D; Sniderman S; Ballard R; Phibbs RH
J Pediatr; 1991 Jun; 118(6):949-55. PubMed ID: 2040933
[TBL] [Abstract][Full Text] [Related]
19. The future of r-HuEPO.
Eschbach JW
Nephrol Dial Transplant; 1995; 10 Suppl 2():96-109. PubMed ID: 7644114
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin in the treatment of the anaemia of cancer.
Abels RI
Acta Haematol; 1992; 87 Suppl 1():4-11. PubMed ID: 1574966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
